U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C59H84N18O14
Molecular Weight 1269.4128
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GOSERELIN

SMILES

CC(C)C[C@@]([H])(C(=N[C@@]([H])(CCCNC(=N)N)C(=O)N1CCC[C@@]1([H])C(=NNC(=N)O)O)O)N=C([C@@]([H])(COC(C)(C)C)N=C([C@]([H])(Cc2ccc(cc2)O)N=C([C@]([H])(CO)N=C([C@]([H])(Cc3c[nH]c4ccccc34)N=C([C@]([H])(Cc5cnc[nH]5)N=C([C@]6([H])CCC(=N6)O)O)O)O)O)O)O

InChI

InChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N
InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1

HIDE SMILES / InChI

Molecular Formula C59H84N18O14
Molecular Weight 1269.4128
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/zoladex.html

Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels. Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. Goserelin is marketed under the brand names Zoladex, by AstraZeneca, or goserelin acetate.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL612518
0.82 nM [IC50]
1.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZOLADEX

Approved Use

ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate Use as palliative treatment of advanced carcinoma of the prostate

Launch Date

8.6728317E11
Palliative
ZOLADEX

Approved Use

ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate Use as palliative treatment of advanced carcinoma of the prostate

Launch Date

8.6728317E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.46 ng/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.84 ng/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.79 μg/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.9 μg/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
9.5 μg/L
250 μg 1 times / day multiple, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: MULTIPLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.5 μg/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3 ng/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
8.85 ng/mL
10.8 mg single, subcutaneous
dose: 10.8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18.5 ng × day/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
27.8 ng × day/mL
3.6 mg single, subcutaneous
dose: 3.6 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
36.9 μg × h/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
41.3 μg × h/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
44 μg × h/L
250 μg 1 times / day multiple, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: MULTIPLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
44.5 μg × h/L
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.2 h
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.3 h
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
5 h
250 μg 1 times / day multiple, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: MULTIPLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.6 h
250 μg single, subcutaneous
dose: 250 μg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
73%
10.8 mg single, subcutaneous
dose: 10.8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
GOSERELIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Other AEs: Fatigue, Hot flashes...
Other AEs:
Fatigue (grade 2, 2 patients)
Hot flashes (grade 2, 29 patients)
Menses irregular (grade 2, 5 patients)
Libido decreased (grade 2, 9 patients)
Agitation (grade 2, 6 patients)
Anxiety (grade 2, 9 patients)
Depression (grade 2, 8 patients)
Muscle pain (grade 2, 1 patient)
Headache (grade 2, 12 patients)
Sweating (grade 2, 10 patients)
Thromboembolism (grade 4, 1 patient)
Dryness vaginal (grade 2, 12 patients)
Hot flashes (grade 3, 4 patients)
Menses irregular (grade 3, 2 patients)
Depression (grade 3, 1 patient)
Sources:
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
after 90 days of radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Other AEs: Diarrhea, Cystitis...
Other AEs:
Diarrhea (36%)
Cystitis (16%)
Bleeding rectal (14%)
Proctitis (8%)
Hematuria (7%)
Sources:
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Other AEs: Gastrointestinal disorder (NOS), Bladder disorder NOS...
Other AEs:
Gastrointestinal disorder (NOS) (80%)
Bladder disorder NOS (58%)
Skin and subcutaneous conditions NEC (37%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Muscle pain grade 2, 1 patient
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Sweating grade 2, 10 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Dryness vaginal grade 2, 12 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Headache grade 2, 12 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Fatigue grade 2, 2 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Hot flashes grade 2, 29 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Menses irregular grade 2, 5 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Agitation grade 2, 6 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Depression grade 2, 8 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Anxiety grade 2, 9 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Libido decreased grade 2, 9 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Depression grade 3, 1 patient
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Menses irregular grade 3, 2 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Hot flashes grade 3, 4 patients
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Thromboembolism grade 4, 1 patient
3.6 mg 1 times / day steady, subcutaneous
Recommended
Dose: 3.6 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 3.6 mg, 1 times / day
Co-administed with::
Chemotherapy
Sources:
unhealthy, 18 - 49 years
n = 103
Health Status: unhealthy
Condition: breast cancer
Age Group: 18 - 49 years
Sex: F
Population Size: 103
Sources:
Bleeding rectal 14%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
after 90 days of radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Cystitis 16%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
after 90 days of radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Diarrhea 36%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
after 90 days of radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Hematuria 7%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
after 90 days of radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Proctitis 8%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
after 90 days of radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Skin and subcutaneous conditions NEC 37%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Bladder disorder NOS 58%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Gastrointestinal disorder (NOS) 80%
10.8 mg 1 times / day steady, subcutaneous
Recommended
Dose: 10.8 mg, 1 times / day
Route: subcutaneous
Route: steady
Dose: 10.8 mg, 1 times / day
Co-administed with::
flutamide
radiation therapy
Sources:
unhealthy, adult
n = 231
Health Status: unhealthy
Condition: Prostatic Carcinoma
Age Group: adult
Sex: M
Population Size: 231
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Severe toxic hepatitis during flutamide (Eulexin) treatment].
1989 Jan 16
Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy.
1997
[A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer].
1997 Jul
Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma.
1999 Mar
Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms.
2000
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.
2002 Sep
Cirrhosis with steatohepatitis following longterm stilboestrol treatment.
2003 Aug
Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.
2004 Apr
Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
2004 May
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
2005 Feb 14
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
2005 Jun
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
2006 Jul
A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
2007 Nov
Death due to liver failure during endocrine therapy for premenopausal breast cancer.
2010 Aug
Patents

Sample Use Guides

ZOLADEX (Goserelin), at a dose of 3.6 mg, should be administered subcutaneously every 28 days into the anterior abdominal wall below the navel line using an aseptic technique under the supervision of a physician
Route of Administration: Other
In Vitro Use Guide
Goserelin significantly inhibited LNCaP cell proliferation at doses between 10(-9)-10(-6) M.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:14:57 UTC 2021
Edited
by admin
on Fri Jun 25 21:14:57 UTC 2021
Record UNII
0F65R8P09N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GOSERELIN
EP   HSDB   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
GOSERELIN [HSDB]
Common Name English
1-(5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TYROSYL-O-TERT-BUTYL-D-SERYL-L-LEUCYL-L-ARGINYL-L-PROLYL)SEMICARBAZIDE
Common Name English
ICI 118,630
Code English
GOSERELIN [EP MONOGRAPH]
Common Name English
LUTEINIZING HORMONE-RELEASING FACTOR (PIG), 6-(O-(1,1-DIMETHYLETHYL)-D-SERINE)-10-DEGLYCINAMIDE-, 2-(AMINOCARBONYL)HYDRAZIDE
Common Name English
GOSERELIN [INN]
Common Name English
GOSERELIN [WHO-DD]
Common Name English
GOSERELIN [USAN]
Common Name English
GOSERELIN [MART.]
Common Name English
ICI-118630
Code English
GOSERELIN [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1910
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
LIVERTOX 466
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
NDF-RT N0000175655
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
WHO-VATC QL02AE03
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
WHO-ATC L02AE03
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
NDF-RT N0000175654
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
Code System Code Type Description
DRUG BANK
DB00014
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201247
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
EPA CompTox
65807-02-5
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
CAS
65807-02-5
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
HSDB
7606
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
IUPHAR
3879
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
DRUG CENTRAL
1327
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
EVMPD
SUB07962MIG
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
PUBCHEM
5311128
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
FDA UNII
0F65R8P09N
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
MESH
D017273
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
MERCK INDEX
M5832
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C1374
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
RXCUI
50610
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY RxNorm
INN
5943
Created by admin on Fri Jun 25 21:14:57 UTC 2021 , Edited by admin on Fri Jun 25 21:14:57 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC